Stemline Therapeutics, Inc. Announces Pricing of Initial Public Offering of 3,317,644 Shares of Common Stock

[at noodls] – NEW YORK, Jan. 28, 2013 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor … more

View todays social media effects on STML

View the latest stocks trending across Twitter. Click to view dashboard

See who Stemline is hiring next, click here to view